Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

Rhea-AI Summary

Applied Molecular Transport (AMTI) will disclose top-line results from its Phase 2 FILLMORE trial of AMT-101, aimed at treating chronic pouchitis, on April 25, 2022. The trial focuses on the effectiveness of this GI-selective oral fusion of IL-10. The data will be shared during a premarket conference call at 8:30 a.m. ET. The company, based in South San Francisco, specializes in developing novel oral biologic candidates for autoimmune and inflammatory diseases using its proprietary technology to enhance therapeutic transport across the intestinal barrier.

Positive

• Upcoming presentation of top-line results from Phase 2 trial for AMT-101
• Focus on addressing chronic pouchitis with a novel oral biologic
• Potential to impact shareholder value positively based on trial results

Negative

• None.

- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 FILLMORE monotherapy trial for AMT-101 (GI- selective, oral fusion of IL-10) in patients with chronic pouchitis in a premarket press release and webcasted conference call on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT).

Conference Call & Webcast Information
To participate in the conference call, please dial (844) 422-9742 (Domestic) or (706) 758-6032 (International) and refer to conference ID 5649019. The live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events.

About Applied Molecular Transport Inc. 
AMT is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT is developing additional oral biologic product candidates in patient-friendly oral dosage forms that are designed to either target local intestinal tissue or enter systemic circulation to precisely address the relevant pathophysiology of disease.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com. 

Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com

Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com 

FAQ

What are the results of the Phase 2 FILLMORE trial for AMT-101?

The top-line results will be announced on April 25, 2022, during a conference call.

How does AMT-101 work?

AMT-101 is a GI-selective oral fusion of IL-10 designed to treat chronic pouchitis.

What time will the AMTI conference call be held?

The conference call is scheduled for April 25, 2022, at 8:30 a.m. ET.

Where can I listen to the AMTI conference call?

The call can be accessed via the Events page on the Applied Molecular Transport website.